LUCD (Lucid Diagnostics) Total Debt per Share: $0.16 (As of Mar. 2026)


LUCD Lucid Diagnostics Inc LUCD
20 GF Score
Price $1.00
GF Value $0.82
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Total Debt per Share?

Lucid Diagnostics LUCD +2.03% 20 Total Debt per Share is $0.16 as of Mar. 2026. GuruFocus rates LUCD with a GF Score™ of 20/100 and a GF Value™ of $0.82 (Modestly Overvalued). The stock has 5 warning signs investors should review.

$0.16 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Lucid Diagnostics's Total Debt Per Share for the quarter that ended in Mar. 2026 was $0.16.

Lucid Diagnostics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Lucid Diagnostics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics Total Debt per Share Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial 0.00 0.05 0.36 0.34 0.20

Lucid Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.27 0.19 0.20 0.16
LUCD
20GF Score
Lucid Diagnostics Inc LUCD
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lucid Diagnostics Total Debt per Share Calculation

Lucid Diagnostics's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.93+24.89)/131.10
=0.20

Lucid Diagnostics's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.70+26.11)/164.88
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.16 mean?
Lucid Diagnostics (LUCD) has a Total Debt per Share of $0.16 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Lucid Diagnostics and its competitors.
Is Lucid Diagnostics' Total Debt per Share too high?
Lucid Diagnostics' current Total Debt per Share is $0.16. Overall, Lucid Diagnostics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Total Debt per Share compare to QTRX and INFU?
Lucid Diagnostics' Total Debt per Share of $0.16 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Devices & Instruments company?
A good Total Debt per Share depends on the Medical Devices & Instruments industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Lucid Diagnostics and its competitors. Lucid Diagnostics's current Total Debt per Share is $0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.82, compared to a current price of $1.00 — trading 22% above its estimated fair value. The current Total Debt per Share is $0.16. Lucid Diagnostics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Total Debt per Share is $0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $1.00 is trading 22% above its estimated GF Value™ of $0.82. GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.

Key valuation signals for LUCD:

  • Total Debt per Share: $0.16
  • GF Value™: $0.82 vs. price of $1.00 (22% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
20GF Score

Get the complete analysis for LUCD

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price
$0.82
GF Value